Science News

... from universities, journals, and other research organizations

Relapsed Smokers Can Be Successfully Re-Treated

Mar. 29, 2001 — PORTLAND, Ore. – In one of the first "recycling" studies to examine people who attempt to quit smoking after first failing medical treatment, researchers at Oregon Health Sciences University and their colleagues found abstinence rates five times greater for participants taking bupropion compared to participants taking a placebo. Study results are being presented at 12 p.m. on Saturday, March 24, at the Society for Research on Nicotine and Tobacco Annual Meeting in Seattle.


Share This:

"Patients often feel discouraged following treatment with medications such as bupropion or nicotine patches if they are unable to successfully quit smoking," said David Gonzales, Ph.D., director of the OHSU Smoking Cessation Center and lead author of the study results. "However, evidence-based options for patients in this situation have been few. This is the first study to show that smokers can be retreated with bupropion successfully."

Bupropion, marketed in sustained release form as Zyban, is a nicotine-free prescription medication designed to reduce nicotine cravings and other symptoms normally associated with nicotine withdrawal. The multicenter study involved 450 adult cigarette smokers who averaged 15 cigarettes per day prior to the study, and who had been unable to quit or had relapsed after a previous course of bupropion. Study participants were randomly selected to receive bupropion SR or a placebo.

Typically, people who attempt to quit smoking on their own experience 5 percent to 7 percent success rates, while smokers who try bupropion a first time generally enjoy a better-than-30 percent long-term success rate. In this study, smokers re-treated with the drug had a 27 percent abstinence rate after seven weeks, compared to 5 percent abstinence for the placebo group. At 12 weeks, 20 percent of smokers being re-treated were still smoke free compared to three percent of the subjects in the placebo group.

Zyban is marketed by GlaxoSmithKline Pharmaceuticals.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

|

Story Source:

The above story is reprinted from materials provided by Oregon Health Sciences University.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


APA

MLA

Note: If no author is given, the source is cited instead.

Search ScienceDaily

Number of stories in archives: 137,427

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily's archives for related news topics,
the latest news stories, reference articles, science videos, images, and books.

Recommend ScienceDaily on Facebook, Twitter, and Google:

Other social bookmarking and sharing services:

|

 
  more breaking science news

Social Networks


Follow ScienceDaily on Facebook, Twitter,
and Google:

Recommend ScienceDaily on Facebook, Twitter, and Google +1:

Other social bookmarking and sharing tools:

|

Breaking News

... from NewsDaily.com

In Other News ...

Science Video News


Surviving Heart Failure

Inflammations that occur after a heart attack can be a severe complication that further damages the heart. Cardiologists are now trying a new. ...  > full story

Strange Science News

 

Free Subscriptions

... from ScienceDaily

Get the latest science news with our free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Feedback

... we want to hear from you!

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?

Post this page to your favorite social bookmarking site:
Include this item in your blog or web site:
Cite this article in your essay, paper, or report:
Email this page's link to a friend or colleague: